At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CLDX Celldex Therapeutics
Pre-Mkt 03-23 04:16:15 EDT
30.90
+0.87
+2.90%
High31.85Low29.95Vol3.24M
Open30.26D1 Closing30.03Amplitude6.33%
Mkt Cap2.05BTradable Cap1.64BTotal Shares66.45M
T/O100.01MT/O Rate6.09%Tradable Shares53.21M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Celldex Therapeutics Is Maintained at Neutral by Goldman Sachs
Dow Jones  ·  03-03
Celldex Therapeutics Is Maintained at Neutral by Goldman Sachs
Cantor Fitzgerald Reaffirms Their Buy Rating on Celldex (CLDX)
TIPRANKS  ·  03-02
Cantor Fitzgerald Reaffirms Their Buy Rating on Celldex (CLDX)
Celldex presents new data from Phase 2 ColdU, SD Open Label Extension
TIPRANKS  ·  03-02
Celldex presents new data from Phase 2 ColdU, SD Open Label Extension
Celldex reports Phase 2 data showing barzolvolimab retreatment restores strong efficacy in cold urticaria and symptomatic dermographism
Reuters  ·  03-01
Celldex reports Phase 2 data showing barzolvolimab retreatment restores strong efficacy in cold urticaria and symptomatic dermographism
Guggenheim Sticks to Their Buy Rating for Celldex (CLDX)
TIPRANKS  ·  03-01
Guggenheim Sticks to Their Buy Rating for Celldex (CLDX)
Celldex reports positive Phase 2 barzolvolimab data in chronic urticaria at AAAAI 2026
Reuters  ·  02-28
Celldex reports positive Phase 2 barzolvolimab data in chronic urticaria at AAAAI 2026
Celldex Therapeutics Price Target Raised to $68.00/Share From $58.00 by Stifel
Dow Jones  ·  02-26
Celldex Therapeutics Price Target Raised to $68.00/Share From $58.00 by Stifel
Celldex Therapeutics Inc : Stifel Raises Target Price to $68 From $58
THOMSON REUTERS  ·  02-26
Celldex Therapeutics Inc : Stifel Raises Target Price to $68 From $58
Morgan Stanley Lifts Price Target on Celldex Therapeutics to $44 From $43, Keeps Overweight Rating
MT Newswires Live  ·  02-26
Morgan Stanley Lifts Price Target on Celldex Therapeutics to $44 From $43, Keeps Overweight Rating
Celldex Therapeutics: Early EMBARQ Enrollment and 2026 Data Catalysts Underscore Attractive Risk‑Reward and Support Buy Rating
TIPRANKS  ·  02-26
Celldex Therapeutics: Early EMBARQ Enrollment and 2026 Data Catalysts Underscore Attractive Risk‑Reward and Support Buy Rating
Celldex Therapeutics Inc : Morgan Stanley Raises Target Price to $44.00 From $43.00
THOMSON REUTERS  ·  02-26
Celldex Therapeutics Inc : Morgan Stanley Raises Target Price to $44.00 From $43.00
Barclays Reaffirms Their Sell Rating on Celldex (CLDX)
TIPRANKS  ·  02-26
Barclays Reaffirms Their Sell Rating on Celldex (CLDX)
Celldex Q4 net loss hits USD 81.3 million as Q4 revenue totals USD 0.1 million (-89.7%)
Reuters  ·  02-26
Celldex Q4 net loss hits USD 81.3 million as Q4 revenue totals USD 0.1 million (-89.7%)
Celldex Therapeutics Q4 EPS USD -1.22 VS. Ibes Estimate USD -1.01
THOMSON REUTERS  ·  02-26
Celldex Therapeutics Q4 EPS USD -1.22 VS. Ibes Estimate USD -1.01
Celldex Therapeutics Up Over 19%, on Pace for Largest Percent Increase Since February 2024 -- Data Talk
Dow Jones  ·  02-26
Celldex Therapeutics Up Over 19%, on Pace for Largest Percent Increase Since February 2024 -- Data Talk
Celldex Shares Rise After Barzolvolimab Study Completes Enrollment Early
Dow Jones  ·  02-25
Celldex Shares Rise After Barzolvolimab Study Completes Enrollment Early
Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), Celldex (CLDX)
TIPRANKS  ·  02-25
Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), Celldex (CLDX)
BRIEF-Celldex Completes Enrollment In Global Phase 3 Studies (Embarq-Csu1 And Embarq-Csu2) Of Barzolvolimab In Chronic Spontaneous Urticaria
Reuters  ·  02-25
BRIEF-Celldex Completes Enrollment In Global Phase 3 Studies (Embarq-Csu1 And Embarq-Csu2) Of Barzolvolimab In Chronic Spontaneous Urticaria
Celldex Completes Enrollment in Global Phase 3 Studies (Embarq-Csu1 and Embarq-Csu2) of Barzolvolimab in Chronic Spontaneous Urticaria
THOMSON REUTERS  ·  02-25
Celldex Completes Enrollment in Global Phase 3 Studies (Embarq-Csu1 and Embarq-Csu2) of Barzolvolimab in Chronic Spontaneous Urticaria
Celldex Therapeutics Inc - Topline Data Expected Q4 2026
THOMSON REUTERS  ·  02-25
Celldex Therapeutics Inc - Topline Data Expected Q4 2026

Introduction

Company Name.
Celldex Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Issue price:
--